Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Choroid plexus cell replacement therapy - Living Cell Technologies

Next Previous
Drug Profile

Choroid plexus cell replacement therapy - Living Cell Technologies

Alternative Names: Neurological disorders cell therapy - Living Cell Technologies; NeurotrophinCell; NTCELL

Latest Information Update: 28 Jun 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Living Cell Technologies
  • Developer Auckland UniServices; Living Cell Technologies; University of Auckland
  • Class Antidementias; Antiparkinsonians; Cell therapies; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Cell replacements; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Parkinson's disease
  • No development reported Alzheimer's disease; Hearing loss; Huntington's disease; Osteoarthritis; Osteoporosis; Retinal disorders; Spinal cord injuries; Stroke; Wounds

Most Recent Events

  • 28 Jun 2021 No recent reports of development identified for research development in Alzheimer's-disease in New Zealand
  • 28 Jan 2020 No recent reports of development identified for preclinical development in Hearing loss in New Zealand (Intrastriatal, Injection)
  • 28 Jan 2020 No recent reports of development identified for preclinical development in Huntington's-disease in New Zealand (Intrastriatal, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top